Rapid and proven production of transplastomic tobaccoplants by restoration of pigmentation and photosynthesis
Sebastian M. J. Klaus, Fong-Chin Huang, Christian Eibl, Hans-Ulrich Koopà and Timothy J. GoldsICON Genetics AG, Research Centre Freising, Lise-Meitner-Str. 30, 85354 Freising, Germany
Received 9 May 2003; revised 5 June 2003; accepted 13 June 2003. ÃFor correspondence (fax þ49 89 17861165; e-mail koop@icongenetics.de).
Tobacco chloroplast transformation is typically achieved using dominant, selectable antibiotic resistancegenes such as aadA, nptII and aphA-6. An improvement would be the combination of such a marker with avisual screening system for the early and conclusive detection of plastid transformants. As such, we inves-tigated the use of three photosynthesis-deficient plastid mutants, DpetA, Dycf3 and DrpoA, for thedevelopment of a phenotypic selection system. Mutant plants were used as an alternative to the wild-type as source tissue for transformation, re-introducing deleted plastid sequences and using the aphA-6gene as a selection marker. The reconstitution of the deleted genes in transformed regenerants resulted inshoots with a visually distinct phenotype comparable to the wild-type. This transformation/selectionsystem overcomes the common problems associated with plastid transformation, e.g. the recovery ofspontaneous mutants or nuclear insertions. In addition to the benefits offered by phenotypic selection,phenotype reconstitution leads to restoration of photosynthesis, which we assume drives reconstitutedplants rapidly towards homoplasmy. As such, repeated cycles of regeneration in the presence of anantibiotic selection agent are no longer required.
Keywords: tobacco plastid transformation, chloroplast mutants, antibiotic selection, petA, ycf3, rpoA.
Compared to conventional nuclear transformation, the
advantages of expressing genes in plastids are numerous
(Kavanagh et al., 1994). In tobacco, vectors containing seg-
and have been extensively reviewed (Bock and Hagemann,
ments of tobacco plastid DNA carrying specific point muta-
2000; Daniell et al., 2002; Maliga, 2002). To date, four domi-
tions in the 16S rRNA gene (giving resistance to
nant selectable markers have been described for plastid
spectinomycin and streptomycin) were initially used to
transformation in higher plants: the aadA gene (aminogly-
demonstrate the principle of plastid transformation in
coside adenyltransferase) detoxifying spectinomycin and
tobacco (Svab et al., 1990). However, in this pioneering
streptomycin (Svab and Maliga, 1993), the nptII and aphA-6
work, the transformation frequencies were extremely
genes (aminoglycoside phosphotransferases) detoxifying
low; from a total of 62 spectinomycin-resistant cell lines,
kanamycin (Carrer et al., 1993; Huang et al., 2002) and the
only three were shown to be plastid transformants, the rest
badh gene (betaine aldehyde dehydrogenase) in combina-
were spontaneous mutants. The recovery of spectinomy-
tion with betaine aldehyde as a selection agent (Daniell
cin-resistant mutants also remains an issue where the aadA
et al., 2001). A major disadvantage of such selection sys-
gene is used as a plastid marker. During the last decade, the
tems is that they can produce ‘false positives’ (a term used
aadA gene has been used for the production of plastid
throughout this paper to describe all selected regenerants,
transformants in tobacco (Svab and Maliga, 1993) and other
which are not true plastid transformants). Random point
species like Arabidopsis (Sikdar et al., 1998), potato (Sidorov
mutations within plastid-encoded genes can result in the
et al., 1999) and tomato (Ruf et al., 2001). All of these
insensitivity to some antibiotics. Such a phenomenon
reports describe the recovery of false positives because
has been documented for the antibiotics spectinomycin,
of the occurrence of spontaneous spectinomycin-resistant
Therapeutx™, the makers of Maori Miracle®, researches & develops evidence-based remedies for the safe, effective treatment of human disorders, disease prevention and the maintenance of good health. Maori Miracle® is a unique and superior arthritis formula, designed to treat arthritic symptoms, reduce inflammation, relieve pain, rebuild worn cartilage and improve joint & muscle functio
THE GLOBAL PHARMACEUTICAL INDUSTRY Sarah Holland* and Bernardo Bátiz-Lazo** The case looks at the development of the ethical pharmaceutical industry. The various forces affecting the discovery, development, production, distribution and marketing of prescription drugs are discussed in terms of their origins and recent developments. Readers are then invited to consider trends for the futur